m+Medelevator.RU
← Поиск публикаций
Frontiers in medicine · 2026

Real-world effectiveness of MiSight 1 Day contact lenses in Taiwanese children: a multicenter retrospective study.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Huang Yu-Te, Wang I-Ming, Huang Yu-Hsuan, Lin Pi-Jung, Su Hao-Lin, Tsai Tzu-Hsun, Liu Yao-Lin, Wang I-Jong, Lin Hui-Ju

Аннотация

PURPOSE: To evaluate the real-world effectiveness of MiSight 1 Day soft contact lenses for myopia control in Taiwanese children using age-, sex-, and percentile-matched axial length (AL) references.

METHODS: Retrospective multicenter study across 23 Universal Eye Center clinics. Children aged 6-18 years who initiated MiSight between October 2020 and July 2022 and completed ≥12 months of follow-up were included. Spherical equivalent (SE) and AL were extracted from clinical records and annualized. Observed AL change was compared with matched Taiwanese normative percentiles to estimate axial suppression. Subgroups included age, baseline AL percentile, and prior treatment history.

RESULTS: A total of 368 eyes from 368 patients were analyzed (mean age 11.8 ± 2.3 years; 52% female; mean follow-up 19.2 ± 5.0 months). Mean SE progression was -0.41 ± 0.42 D/year. Mean AL elongation was 0.17 mm/year, corresponding to a mean AL suppression of 0.06 mm/year relative to matched Taiwanese norms. Visual performance was favorable, with 98% achieving ≥20/25. Outcomes were similar across prior treatment groups, including previous atropine or orthokeratology exposure.

CONCLUSION: In routine Taiwanese practice, MiSight 1 Day provided meaningful myopia control and maintained good vision. AL growth was reduced by 27% versus matched normative expectations. These findings support the translational effectiveness of MiSight and emphasize the value of regional normative benchmarks for clinical interpretation.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты